List of Excipients in Branded Drug MUTAMYCIN

« Back to Dashboard

Generic Drugs Containing MUTAMYCIN

Company	Ingredient	NDC	Excipient
Accord BioPharma Inc	mitomycin	69448-003	MANNITOL

What are the Most Frequently-Used Excipients in MUTAMYCIN?

# Of NDCs	Excipient
1	MANNITOL

Mutamycin Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Mutamycin is the historical brand name for mitomycin for injection, a sterile lyophilized cytotoxic product. Its original formulation uses mitomycin C with mannitol as the principal excipient. The active ingredient and original formulation are old, leaving limited value in a conventional product revival. Commercial opportunities are concentrated in improved stability, ready-to-use delivery, intravesical administration, localized drug delivery, and manufacturing advantages rather than in a new basic composition claim.

What is Mutamycin and which excipients does it contain?

Mutamycin is mitomycin for injection, USP. Mitomycin C is an alkylating antineoplastic agent used in combination chemotherapy and, in other products, for localized treatment of urothelial cancer. The historical injectable presentation is a sterile powder requiring reconstitution before administration.[1]

Product attribute	Mutamycin profile
Active ingredient	Mitomycin, commonly referred to as mitomycin C
Dosage form	Sterile lyophilized powder for injection
Historical strengths	5 mg, 20 mg, and 40 mg vials
Principal excipient	Mannitol
Preservative	No preservative in the conventional single-dose vial
Administration	Intravenous use under the approved injectable label
Handling	Cytotoxic-drug precautions and controlled reconstitution
Formulation objective	Improve powder stability and provide a rapidly dissolving sterile cake

The historical product uses mannitol as a bulking agent and lyoprotectant. The excipient also helps form an acceptable lyophilized cake and supports rapid reconstitution. The commercial product is not an aqueous ready-to-use solution.

Mitomycin is chemically reactive and requires controlled storage, light protection, and careful handling. The product label warns that the drug can cause severe tissue injury if extravasation occurs and that personnel must use appropriate cytotoxic handling procedures.[1]

What excipient strategy is used in the Mutamycin formulation?

The conventional excipient strategy is simple: use mannitol to support lyophilization while limiting the number of formulation components in a cytotoxic injectable.

Mannitol provides several technical benefits:

• Bulking of the lyophilized cake.
• Improved physical appearance after freeze-drying.
• Support for reconstitution.
• Low contribution to reactive impurity formation compared with more chemically active excipients.
• Established regulatory precedent in sterile injectable products.

The formulation strategy has limitations. Mannitol does not solve all stability problems associated with mitomycin. A commercial developer would need to evaluate pH, residual moisture, oxygen exposure, light transmission, reconstitution time, particulate formation, potency loss, and degradation products.

Potential formulation variables include:

Formulation variable	Commercial relevance
Mannitol concentration	Controls cake structure, reconstitution, and tonicity
Buffer system	Can affect mitomycin degradation and injectable pH
Residual moisture	Influences solid-state stability
Oxygen control	May reduce oxidative degradation
Container closure	Determines moisture and oxygen ingress
Light protection	Reduces exposure-related degradation
Reconstitution diluent	Affects stability and administration workflow
Vial size	Determines waste, dosing flexibility, and pharmacy economics

A developer should avoid assuming that a direct mannitol substitution is commercially defensible. Mannitol is widely used in injectable products, and a basic mannitol-based composition would likely face weak composition-of-matter protection. Differentiation would need to come from measurable performance, such as longer refrigerated stability, room-temperature storage, faster reconstitution, reduced particulate formation, or lower preparation waste.

What formulations are protected by Mutamycin patents?

The commercial patent position for the historical Mutamycin product is weak compared with modern specialty drugs. Mitomycin is an old small-molecule drug, and the original product-era composition and use claims are expected to be expired or otherwise unavailable as a meaningful barrier to generic entry.

Patent category	Mutamycin position	Strategic assessment
Mitomycin composition of matter	Expired or unavailable	No meaningful protection
Conventional mannitol lyophilized vial	Likely expired or difficult to protect broadly	Low patent strength
Basic injectable use	Old and generally vulnerable	Low barrier
Manufacturing process	Potentially protectable if novel	Moderate only if process-specific
Stabilized lyophilized formulation	Potential opportunity	Requires comparative stability data
Ready-to-use solution	Potential opportunity	Higher development and packaging burden
Intravesical delivery system	Separate product opportunity	Stronger differentiation potential
Sustained-release local delivery	Potential opportunity	Requires device, formulation, or method claims

No active patent estate comparable to that of a recently approved branded oncology product is generally associated with Mutamycin itself. Patent value would more likely attach to a new formulation, delivery vehicle, container system, or treatment method than to the historical brand.

When does Mutamycin lose exclusivity?

Mutamycin has no meaningful remaining exclusivity based on the age of mitomycin and the longstanding availability of mitomycin injectable products. The relevant commercial question is therefore not the expiration of original exclusivity but whether a developer can create a differentiated product that supports regulatory and patent protection.

Mitomycin products are generally subject to the abbreviated new drug application pathway when the proposed product is pharmaceutically equivalent and therapeutically equivalent to the reference product. A conventional generic can compete primarily on price, supply reliability, contract access, and shortage performance.

A modified formulation may require a 505(b)(2) application if it differs materially from an approved injectable product in formulation, route, delivery system, dosing, or clinical use. A 505(b)(2) strategy could provide three to five years of regulatory exclusivity for qualifying new clinical or formulation innovation, depending on the approval basis and applicable FDA exclusivity rules.[2]

What is the Orange Book status of Mutamycin?

The Orange Book is relevant to approved mitomycin products and listed reference products, but the historical Mutamycin brand does not provide a strong current exclusivity platform. The Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patents, and exclusivity information. A conventional mitomycin generic applicant would assess the listed reference product, any listed patents, and the regulatory status of the specific presentation.[2]

For commercial planning, the key Orange Book conclusions are:

1. Mitomycin is a small-molecule drug, not a biologic, so biosimilar pathways do not apply.
2. A standard injectable generic would generally use an ANDA pathway.
3. A novel localized or controlled-release formulation may require a 505(b)(2) pathway.
4. Any current patent protection would attach to the specific approved product or formulation, not to the historical Mutamycin name alone.
5. The discontinued or inactive status of a brand presentation does not by itself eliminate the need to identify the correct reference listed drug.

Which companies are challenging Mutamycin or competing with it?

Competition is primarily from generic mitomycin manufacturers and from differentiated mitomycin products rather than from branded products challenging the Mutamycin brand.

Generic competition has historically included manufacturers such as Teva, Accord Healthcare, and other suppliers of mitomycin for injection, subject to changing market participation and supply status. The relevant competitive factors are manufacturing continuity, sterile-facility capacity, vial availability, hospital contracting, and shortage resilience.

The most important differentiated competitor is Jelmyto, UroGen Pharma's mitomycin pyelocalyceal formulation. The FDA approved Jelmyto in 2021 for adult patients with low-grade upper tract urothelial cancer following complete response to initial treatment.[3] Jelmyto uses a reverse-thermal hydrogel delivery system to retain mitomycin in the upper urinary tract. It is not a direct substitute for Mutamycin injection, but it demonstrates the commercial value of changing the delivery system around an old cytotoxic drug.

Product	Formulation model	Primary use	Competitive significance
Mutamycin	Lyophilized injectable powder	Systemic oncology use	Low differentiation
Generic mitomycin injection	Lyophilized injectable powder	Systemic and procedure-related use	Price and supply competition
Jelmyto	Mitomycin in a pyelocalyceal hydrogel system	Upper tract urothelial cancer	Higher-value localized delivery
Future ready-to-use product	Stable aqueous or reconstituted presentation	Hospital and procedural use	Workflow and safety differentiation

What commercial opportunities exist for improved Mutamycin formulations?

The strongest opportunities are products that reduce pharmacy preparation, improve administration control, or create new local exposure patterns.

Ready-to-use mitomycin injection

A ready-to-use solution could reduce reconstitution steps, occupational exposure, preparation time, and pharmacy waste. The principal technical barriers are chemical stability, container compatibility, microbial control, and acceptable shelf life.

Potential product designs include:

• Single-dose prefilled syringes.
• Small-volume glass vials.
• Polymer containers with oxygen and light protection.
• Dual-chamber systems separating drug and diluent until use.
• Pharmacy-ready bags with validated stability.

A ready-to-use product would face higher development costs than a conventional generic but could support hospital purchasing advantages if it reduces preparation labor and hazardous-drug handling.

Improved lyophilized vial

A next-generation lyophilized vial is the lowest-risk formulation opportunity. Improvements could include:

• Faster reconstitution.
• Lower residual moisture.
• Better cake integrity.
• Reduced foaming.
• Longer room-temperature stability.
• More efficient vial sizes.
• Lower residual drug after transfer.

This route could support an ANDA if the product remains pharmaceutically equivalent, or a 505(b)(2) application if the formulation and labeling create a material difference.

Intravesical mitomycin

Intravesical use is commercially important because mitomycin is used in bladder cancer treatment and in certain urologic procedures. However, an intravesical product requires its own development strategy. The formulation must address bladder residence time, urinary dilution, drug exposure, catheter administration, and occupational handling.

Opportunities include:

• A premeasured sterile solution.
• A prolonged-residence gel.
• A mucoadhesive formulation.
• A temperature-triggered delivery system.
• A formulation designed for postoperative bladder instillation.

Jelmyto demonstrates that localized delivery can create a distinct commercial product even when the active ingredient is old.[3]

Ophthalmic and antiscarring applications

Mitomycin is also used in ophthalmic procedures, including certain glaucoma and refractive surgery applications, although these uses may be off-label or governed by separate clinical practice standards. A commercial ophthalmic product would require a separate safety and regulatory analysis because ocular exposure, concentration, sterility, preservative status, and dosing precision differ from the injectable product.

A preservative-free, unit-dose ophthalmic presentation could have commercial value if it addresses compounding variability and reduces handling errors. It would not automatically inherit the regulatory status of Mutamycin injection.

How strong is the patent estate for a new Mutamycin excipient formulation?

The patent strength depends on the claim category and the amount of supporting data.

Claim type	Expected strength	Required evidence
Mitomycin plus mannitol	Low	Limited differentiation
Alternative bulking agent	Low to moderate	Stability or manufacturing advantage
Specific pH and buffer range	Moderate	Unexpected stability results
Oxygen-controlled package	Moderate	Comparative degradation and shelf-life data
Ready-to-use stable solution	Moderate to strong	Long-term and accelerated stability
Hydrogel delivery system	Stronger	Residence, exposure, and clinical performance
New method of treating a defined cancer population	Moderate	Clinical differentiation and enforceable indication
Manufacturing process reducing impurities	Moderate	Reproducibility and impurity data

The most defensible patent strategy would combine formulation claims with process, container, and method-of-use claims. A single broad claim covering "mitomycin with an excipient" would face substantial prior-art and obviousness risk.

A practical filing program could include:

1. Provisional application covering the formulation composition.
2. Separate claims for pH, osmolality, residual moisture, and degradation limits.
3. Container-closure and oxygen-control claims.
4. Process claims covering lyophilization and reconstitution.
5. Method claims for a defined localized administration regimen.
6. International filings in the United States, Europe, Japan, and major oncology markets.

What generic entry risks exist for Mutamycin?

Generic entry risk is high for the conventional lyophilized injectable product. The market has limited composition-of-matter protection, the active ingredient is well characterized, and the dosage form is established.

Risk factors include:

• Multiple potential ANDA applicants.
• Low switching costs for hospitals.
• Price-based contracting.
• Limited clinical differentiation.
• Potential shortage-driven entry by alternative suppliers.
• Low tolerance for premium pricing without workflow or safety benefits.

Risk is lower for a differentiated product when the formulation creates clinically relevant advantages. A hydrogel, sustained-release system, or stable ready-to-use presentation may require additional clinical, device, or human-factors evidence and may support stronger patent positions.

What litigation and Paragraph IV issues affect Mutamycin?

No major contemporary patent-litigation platform is generally associated with the historical Mutamycin formulation. A standard generic applicant would evaluate Paragraph IV certification only against patents listed for the relevant reference product. If no unexpired patents are listed, the principal regulatory route would not depend on defeating an active branded patent estate.

Litigation risk would increase for a newer mitomycin product if its sponsor obtained patents covering:

• A specific excipient combination.
• A stabilized liquid formulation.
• A controlled-release hydrogel.
• A delivery device.
• A new dosing regimen.
• A patient-selection method.

For a new formulation, Paragraph IV risk would shift from the old Mutamycin brand to the newer product's Orange Book-listed patents. Litigation exposure would therefore depend on the commercial product selected, not on the age of mitomycin alone.

What licensing opportunities exist for mitomycin excipient technology?

Licensing value is more likely to reside in delivery technology than in the Mutamycin brand. Relevant deal targets include:

• Reverse-thermal hydrogels.
• Mucoadhesive polymers.
• Stable aqueous cytotoxic formulations.
• Prefilled hazardous-drug delivery systems.
• Closed-system transfer devices.
• Long-term sterile packaging.
• Localized oncology implants.

A licensee could combine an established mitomycin API supply chain with proprietary formulation or device technology. The most attractive structure would link milestones to formulation selection, IND or 505(b)(2) acceptance, approval, and commercial supply.

What is the revenue opportunity for a differentiated Mutamycin product?

A conventional mitomycin generic is likely to be a low-margin hospital injectable. Revenue depends on tender access, supply reliability, and manufacturing cost rather than brand loyalty.

A differentiated product could capture higher pricing if it provides:

• Reduced pharmacy compounding labor.
• Lower hazardous-drug exposure.
• Longer shelf life.
• Lower wastage from single-dose packaging.
• Better treatment-site retention.
• Fewer administration steps.
• A new approved indication.

Jelmyto demonstrates the greater commercial potential of a localized mitomycin product compared with a commodity injectable.[3] The revenue opportunity is therefore highest where the formulation changes clinical utility, not merely where it changes the excipient list.

Key Takeaways

• Mutamycin is a historical mitomycin injection product based on a lyophilized powder with mannitol.
• The original active ingredient and conventional formulation provide little remaining exclusivity value.
• Generic entry risk is high for a standard injectable presentation.
• The strongest excipient opportunities involve stable ready-to-use solutions, improved lyophilized cakes, oxygen-controlled packaging, and localized delivery.
• Intravesical and hydrogel formulations offer greater commercial and patent potential than a basic mannitol substitution.
• Mitomycin is a small molecule, so biosimilar risk does not apply.
• A conventional generic would generally use an ANDA, while a materially differentiated formulation may support a 505(b)(2) strategy.
• Licensing value is concentrated in delivery platforms, packaging systems, and formulation technology.

FAQs

Is Mutamycin the same as mitomycin C?

Yes. Mutamycin is the historical brand name for mitomycin for injection, whose active ingredient is mitomycin, commonly called mitomycin C.

Can mannitol be replaced in a new Mutamycin formulation?

Yes, but replacement alone is unlikely to create strong commercial protection. The substitute excipient would need to produce a measurable advantage in stability, reconstitution, storage, safety, or administration.

Is Jelmyto a generic version of Mutamycin?

No. Jelmyto is a differentiated mitomycin product using a pyelocalyceal hydrogel delivery system. It is not a conventional generic injectable equivalent to Mutamycin.[3]

Can an intravesical mitomycin product obtain new patent protection?

Yes. Protection may be available for the hydrogel composition, residence-time characteristics, dosing regimen, delivery device, manufacturing process, or treatment method, subject to prior-art and obviousness analysis.

Does Mutamycin have biosimilar competition?

No. Mitomycin is a chemically synthesized small molecule. Competing products are regulated as generic drugs or, for materially modified formulations, under pathways such as 505(b)(2), not as biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). Mutamycin (mitomycin for injection, USP) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2021). Jelmyto (mitomycin) for pyelocalyceal solution prescribing information.